Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
$2.72
+10.6%
$2.43
$0.80
$3.42
$101.07M-0.8944,059 shs63,569 shs
InflaRx N.V. stock logo
IFRX
InflaRx
$1.25
-2.3%
$1.25
$0.71
$2.82
$85.93M1.4478,612 shs580,865 shs
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
$1.32
+0.8%
$1.38
$0.73
$2.56
$24.98M1.69284,093 shs39.70 million shs
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
$2.10
+6.6%
$1.86
$1.39
$3.81
$92.84M0.58128,807 shs126,353 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
+10.57%+18.26%+10.57%+65.85%+43.16%
InflaRx N.V. stock logo
IFRX
InflaRx
-2.34%-14.97%+1.63%+44.03%-15.54%
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
+0.76%0.00%-4.35%-34.65%+25.71%
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
+6.60%-1.41%+12.90%+13.51%+209,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
$2.72
+10.6%
$2.43
$0.80
$3.42
$101.07M-0.8944,059 shs63,569 shs
InflaRx N.V. stock logo
IFRX
InflaRx
$1.25
-2.3%
$1.25
$0.71
$2.82
$85.93M1.4478,612 shs580,865 shs
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
$1.32
+0.8%
$1.38
$0.73
$2.56
$24.98M1.69284,093 shs39.70 million shs
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
$2.10
+6.6%
$1.86
$1.39
$3.81
$92.84M0.58128,807 shs126,353 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
+10.57%+18.26%+10.57%+65.85%+43.16%
InflaRx N.V. stock logo
IFRX
InflaRx
-2.34%-14.97%+1.63%+44.03%-15.54%
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
+0.76%0.00%-4.35%-34.65%+25.71%
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
+6.60%-1.41%+12.90%+13.51%+209,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
2.00
Hold$5.50102.21% Upside
InflaRx N.V. stock logo
IFRX
InflaRx
2.67
Moderate Buy$6.20396.00% Upside
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
1.00
SellN/AN/A
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
1.50
ReduceN/AN/A

Current Analyst Ratings Breakdown

Latest MIRA, ANEB, WHWK, and IFRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/14/2025
InflaRx N.V. stock logo
IFRX
InflaRx
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/8/2025
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/8/2025
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/7/2025
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong SellHold
9/27/2025
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
InflaRx N.V. stock logo
IFRX
InflaRx
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/2/2025
InflaRx N.V. stock logo
IFRX
InflaRx
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$6.00
8/11/2025
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell
(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/A$0.28 per shareN/A
InflaRx N.V. stock logo
IFRX
InflaRx
$180K466.18N/AN/A$1.13 per share1.11
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/A$0.13 per shareN/A
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
$25.98M3.81N/AN/A$2.12 per share0.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-$8.48M-$0.260.00N/AN/A-80.85%-76.33%N/A
InflaRx N.V. stock logo
IFRX
InflaRx
-$49.85M-$0.800.00N/AN/AN/A-71.76%-57.68%11/14/2025 (Estimated)
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$7.85M-$0.490.00N/AN/AN/A-406.70%-328.44%11/11/2025 (Estimated)
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
-$63.69M-$0.060.00N/A99.42%-75.99%-68.57%N/A

Latest MIRA, ANEB, WHWK, and IFRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/11/2025N/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$0.11N/AN/AN/AN/AN/A
9/29/2025Q4 2025
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-$0.05-$0.05N/A-$0.05N/AN/A
8/14/2025Q2 2025
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$0.11-$0.09+$0.02-$0.09N/AN/A
8/7/2025Q2 2025
InflaRx N.V. stock logo
IFRX
InflaRx
-$0.24-$0.24N/A-$0.24$0.02 million$0.05 million
8/7/2025Q2 2025
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
$0.49-$0.76-$1.25-$0.76$100.00 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/AN/A
InflaRx N.V. stock logo
IFRX
InflaRx
N/AN/AN/AN/AN/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/AN/A
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/A
24.51
24.51
InflaRx N.V. stock logo
IFRX
InflaRx
N/A
4.10
3.78
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/A
2.80
2.80
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
N/A
20.41
20.41

Institutional Ownership

CompanyInstitutional Ownership
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
28.40%
InflaRx N.V. stock logo
IFRX
InflaRx
42.39%
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
35.16%
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
52.08%

Insider Ownership

CompanyInsider Ownership
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
80.60%
InflaRx N.V. stock logo
IFRX
InflaRx
16.30%
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
6.65%
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
49.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
441.08 million7.97 millionNot Optionable
InflaRx N.V. stock logo
IFRX
InflaRx
6067.13 million56.19 millionOptionable
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
219.07 million17.80 millionNot Optionable
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
2147.13 million23.61 millionN/A

New MarketBeat Followers Over Time

Media Sentiment Over Time

Anebulo Pharmaceuticals stock logo

Anebulo Pharmaceuticals NASDAQ:ANEB

$2.72 +0.26 (+10.57%)
Closing price 10/15/2025 04:00 PM Eastern
Extended Trading
$2.70 -0.02 (-0.59%)
As of 10/15/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

InflaRx stock logo

InflaRx NASDAQ:IFRX

$1.25 -0.03 (-2.34%)
Closing price 10/15/2025 04:00 PM Eastern
Extended Trading
$1.26 +0.01 (+0.80%)
As of 10/15/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

MIRA Pharmaceuticals stock logo

MIRA Pharmaceuticals NASDAQ:MIRA

$1.32 +0.01 (+0.76%)
Closing price 10/15/2025 04:00 PM Eastern
Extended Trading
$2.24 +0.92 (+69.32%)
As of 10/15/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Whitehawk Therapeutics stock logo

Whitehawk Therapeutics NASDAQ:WHWK

$2.10 +0.13 (+6.60%)
As of 10/15/2025 04:00 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.